BioXcel Therapeutics, Inc. (BTAIQ) company profile
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
About BioXcel Therapeutics
Pharmaceutical Preparations, SIC 2834
BioXcel Therapeutics, Inc. is a biopharmaceutical company that develops medicines in neuroscience, alongside its wholly owned subsidiary OnkosXcel Therapeutics, which focuses on immuno-oncology. The company utilizes a proprietary artificial intelligence platform designed to identify new therapeutic indications from existing approved drugs or clinical candidates to treat disorders with unmet medical needs. Its commercialized product is IGALMI, a sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation linked to schizophrenia or bipolar I or II disorder in adults. Its clinical pipeline includes BXCL501 for acute agitation across neuropsychiatric conditions and BXCL701 for various aggressive tumors. Target customers encompass healthcare providers, hospitals, integrated delivery networks, and patients requiring agitation management.
The company operates primarily within the United States, commercializing IGALMI through domestic distribution channels while evaluating potential commercial partnerships and third-party collaborations for prospective international distribution. The provided text mentions no international regulatory filings, geographic operational hubs, or specific corporate headquarters location.
Summary of the business section of BioXcel Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BioXcel Therapeutics, Inc.
- Headquarters
- New Haven, CT
- Address
- 555 Long Wharf Drive 06511
- Phone
- (203) 643-8060
- Website
- bioxceltherapeutics.com
- Employees
- 37, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Stamford, Connecticut
Stock & identifiers
- Ticker
- BTAIQ
- Former tickers
- BTAI until Oct 30, 2026
- Exchange
- OTC
- IPO date
- Mar 9, 2018
- Shares outstanding
- 31M, Aug 11, 2026
- Public float
- $11.02M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-16 reverse, Feb 10, 2025
- SEC CIK
- 1720893
- CUSIP
- 09075P204
- ISIN
- US09075P2048
- FIGI
- BBG00K20GVD2
- Share class FIGI
- BBG00K20GW31
- LEI
- 549300Y25FYZ0E8LW260
- EIN
- 82-1386754
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Vimal Mehta | CEO and President, Director | 550,285 |
| Richard I. Steinhart | Chief Financial Officer | 26,335 |
| Javier Rodriguez | See Remarks | 26,838 |
| Frank Yocca | Chief Scientific Officer | 26,210 |
| Susan E. Atkins | Director | – |
| Michal Votruba | Director | – |
| David J. Mack | Director | 20,317 |
| Sandeep Laumas | Director | – |
| Rajiv Patni | Director | – |
| Peter Mueller | Director | 299,795 |
| Michael Patrick Miller | Director | – |
| June Bray | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 | $1.12M | $385.62K | $1.01M | $2 | – |
| FY2023 | $4.73M | -$2.86M | $1.19M | $15 | – |
| FY2022 | $4.56M | $5.37M | $1.57M | $106 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Vimal Mehta, Ph.D. Chief Executive Officer | $1.00M | – | $101.25K | $16.43K | $1.12M | -76% |
| Javier Rodriguez Senior VP and Chief Legal Officer | $423.83K | $181.76K | $398.53K | $8.63K | $1.01M | -10% |
| Richard Steinhart SVP and Chief Financial Officer | $409.87K | $181.76K | $398.34K | $4.13K | $998.22K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 9, 2018
- Offer price
- $11.00
- Securities offered
- 5,454,545
- Gross proceeds
- $60.00M
- Exchange
- Nasdaq
- First trading day
- Mar 8, 2018
- First-day close
- $11.03+0.3%
- Lock-up ends (est.)
- Sep 4, 2018
“Per Share Total Price to the public $ 11.00 $ 59,999,995.00 Underwriting discounts and commissions $ 0.77 $ 4,199,999.65 Proceeds to us (before expenses) 1 $ 10.23 $ 55,799,995.35 1 We refer you to "Underwriting" beginning on page 170 of this prospectus for additional information regarding underwriting compensation”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“We completed these additional restructuring actions to further reduce the workforce by 50%, ending the year ended December 31, 2024 with 37 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 30, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 1, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 28, 2026 | Bankruptcy | Bankruptcy or receivership (8-K Item 1.03) |
| Mar 21, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 20, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 15, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 9, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 5, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?